Abstract
The classical CNS depressants include hypnotics, most antianxiety medications, and alcohol.1–7 This chapter focuses on the benzodiazepines and similar drugs as well as the barbiturates and barbituratelike medications, whereas alcohol is discussed in chapters 3 and 4. Several related compounds including kava and gamma-hydroxybutyric acid (GHB) are also briefly presented here, as their effects resemble those of the more classical drugs of this class.7–9
This is a preview of subscription content, log in via an institution.
Buying options
Tax calculation will be finalised at checkout
Purchases are for personal use only
Learn about institutional subscriptionsPreview
Unable to display preview. Download preview PDF.
References
Hobbs, W. R., Roll, T. W., & Verndoorn, T. A. Hypnotics and sedatives: Ethanol. In J. G. Hardman, L. E. Limbird, P. B. Molinoff, et al. (Eds.), The pharmacological basis of therapeutics (9th ed.). New York: McGraw-Hill, 1995, pp. 399–431.
O’Brien, C. P. Drug addiction and drug abuse. In J. G. Hardman, L. E. Limbird, P. B. Molinoff, et al. (Eds.), The pharmacological basis of therapeutics (9th ed.). New York: McGraw-Hill, 1995, pp. 557–577.
Udhe, T. W., & Tancer, M. E. Benzodiazepine receptor agonists and antagonists. In H. I. Kaplan & B. J. Sadock (Eds.), Comprehensive textbook of psychiatry (6th ed.). Baltimore, MD: Williams and Wilkins, 1995, pp. 1933–1951.
Wesson, D. R., Smith, D. E., Ling, W., & Seymour, R. B. Sedative-hypnotics and tricyclics. In J. H. Lowinson, P. Ruiz, R. B. Millman, & J. G. Langrod (Eds.), Substance abuse: A comprehensive textbook (3rd ed.). Baltimore, MD: Williams & Wilkins, 1996, pp. 223–230.
Clee, W. B. Warning about Zopiclone misuse. Addiction 91:1389–90, 1996.
Gillin, J. C., Buchsbaum, M. S., Valladares-Neto, D. C., et al. Effects of Zolpidem on local cerebral glucose metabolism during non-REM sleep in normal volunteers: A positron emission tomography study. Neuropsy-chopharmacology 15:302–313, 1996.
Marshall, B. E., & Longnecker, D. E. General anesthetics. In J. G. Hardman, L. E. Limbird, P. B. Molinoff, et al. (Eds.), The pharmacological basis of therapeutics (9th ed.). New York: McGraw-Hill, 1995, pp. 307–330.
Foo, H., & Lemon, J. Acute effects of kava, alone or in combination with alcohol, on subjective measures of impairment and intoxication and on cognitive performance. Drug and Alcohol Abuse 16:147–155, 1997.
Galloway, G. P., Frederic, S. L., Staggers, F. E., et al. Gamma-hydroxybutyrate: An emergency drug of abuse. Addiction 92:89–96, 1997.
Nowell, P. D., Mazumdar, S., Buysse, D. J., et al. Benzodiazepines and Zolpidem for chronic insomnia: A meta-analysis of treatment efficacy. Journal of the American Medical Association 278:2170–2177, 1997.
Bloom, F. E. Neurotransmission and the central nervous system. In J. G. Hardman, L. E. Limbird, P. B. Molinoff, et al. (Eds.), The pharmacological basis of therapeutics (9th ed.). New York: McGraw-Hill, 1995, pp. 267–295.
File, S. E. The pharmacology of benzodiazepine tolerance and withdrawal. Clinical Neuropharmacology 15:100A–101A, 1992.
Schuckit, M. A., & Klein, J. L. Correlations between drinking intensity and reactions to ethanol and diazepam in healthy young men. Neuropsychopharmacology 4:157–163, 1991.
Saxon, L., Hjemdahl, P., Hiltunen, A. J., & Borg, S. Effects of flumazenil in the treatment of benzodiazepine withdrawal: A double-blind pilot study. Psychopharmacology 151:153–160, 1997.
Littrell, R., Sage, T., & Miller, W. Meprobamate dependence secondary to carisoprodol (Soma) use. American Journal of Drug and Alcohol Abuse 19:133–134, 1993.
Miller, N. S., & Gold, M. S. Abuse, addiction, tolerance, and dependence to benzodiazepines in medical and nonmedical populations. American Journal of Drug and Alcohol Abuse 17:27–37, 1991.
Busto, U., Sellers, E. M., Naranjo, C. A., et al. Withdrawal reaction after long-term therapeutic use of benzodiazepines. New England Journal of Medicine 315:854–859, 1986.
Cammarano, W. B., Pittet, J. F., Weitz, S., Schlobohm, R. M., & Marks, J. D. Acute withdrawal syndrome related to the administration of analgesic and sedative medications in adult intensive care unit patients. Critical Care Medicine 26:676–684, 1998.
Rickels, K., Case, W. G., Schweizer, E. E., et al. Low-dose dependence in chronic benzodiazepine users: A preliminary report on 119 patients. Psychopharmacology 22:407–415, 1986.
Lader, M., & Morton, S. Benzodiazepine problems. British Journal of Addiction 86:823–828, 1991.
American Psychiatric Association. The diagnostic and statistical manual of mental disorders (4th ed.) Washington, DC: American Psychiatric Press, 1994.
Lader, M. Iatrogenic sedative dependence and abuse—Have doctors learnt caution? Addiction 93:1133–1135, 1998.
Campbell, R., Schaffer, C. B., & Tupin, J. Catatonia associated with glutethimide withdrawal. Journal of Clinical Psychiatry 44:32–33, 1983.
Lader, M., & Frcka, G. Subjective effects during administration and on discontinuation of zopiclone and temazepam in normal subjects. Pharmacopsychiatry 20:67–71, 1987.
Griffiths, R. R., & Weerts, E. M. Benzodiazepine self-administered in humans and laboratory animals: Implications for problems of long-term use and abuse. Psychopharmacology 134:1–37, 1997.
Anthenelli, R. M., & Schuckit, M. A. Alcohol and cerebral depressants. In I. B. Glass (Ed.), The international handbook of addictive behavior. London: Tavistock, 1991, pp. 57–63
Ancoli-Israel, S. All I want is a good night’s sleep. St. Louis, MO: Mosby Publishing Co., 1996.
McClusky, H. Y., Milby, J. B., Switzer, P. K., et al. Efficacy of behavioral versus triazolam treatment in persistent sleep-onset insomnia. American Journal of Psychiatry 148:121–126, 1991.
Schuckit, M. A. A clinical review of medications used in the treatment of sleeping problems in persons with developmental disabilities. Developmental Disabilities: Clinical Insights 5, San Diego Regional Center for the Developmentally Disabled, 1998.
Schuckit, M. A. A clinical review of medications used in the treatment of anxiety disorders in persons with developmental disabilities. Developmental Disabilities: Clinical Insights 4, San Diego Regional Center for the Developmentally Disabled, 1998.
Schuckit, M. A. Treatment of anxiety in patients who abuse alcohol and drugs. In R. Noyes Jr., M. Roth, & G. D. Burrows (Eds.), Handbook of anxiety, Vol. 4: The treatment of anxiety. Amsterdam: Elsevier Science, 1990, pp. 461–480.
Greenblatt, D. J., Harmatz, J. S., Zinny, M. A., & Shader, R. I. Effect of gradual withdrawal on the rebound sleep disorder after discontinuation of triazolam. New England Journal of Medicine 317:722–728, 1987.
Greenblatt, D. J., Harmatz, J. S., Engelhardt, N., & Shader, R. I. Pharmacokinetic determinants of dynamic differences among three benzodiazepine hypnotics. Archives of General Psychiatry 46:326–332, 1989.
Breier, A., & Paul, S. M. The GABA-A/benzodiazepine receptor: Implications for the molecular basis of anxiety. Journal of Psychiatric Research 24:91–104, 1990.
McCloy, R. F. Reversal of conscious sedation by flumazenil: Current status and future prospects. Acta Anaes-thesiologica Scandinavica 108:35–42, 1995.
Whitwam, J. G., & Amrein, R. Pharmacology of flumazenil. Acta Anaesthesiologica Scandinavica 108:3–14, 1995.
Brunton, L. L. Agents affecting gastrointestinal water, flux, and mobility. In J. G. Hardman, L. E. Limbird, P. B. Molinoff, et al. (Eds.), The pharmacological basis of therapeutics (9th ed.). New York: McGraw-Hill, 1995, pp. 917–936.
Malcolm, R., Anton, R. F., Randall, C. L., et al. A placebo-controlled trial of buspirone in anxious inpatient alcoholics. Alcoholism: Clinical and Experimental Research 16:1007–1013, 1992.
Udhe, T. W., & Tancer, M. E. Buspirone. In H. I. Kaplan & B. J. Sadock (Eds.), Comprehensive textbook of psychiatry (6th ed.). Baltimore, MD: Williams and Wilkins, 1995, pp. 1957–1964.
Juergens, S. M. The pharmacology of sedative hypnotics. In A. W. Graham, T. K. Schultz, & B. B. Wilford (Eds.), Principles of addiction medicine (2nd ed.). Chevy Chase, MD: American Society of Addiction Medicine, 1998, pp. 117–129.
Schuckit, M. A. Kava. Vista Hill Foundation Drug Abuse and Alcoholism Newsletter, 18(2), 1989.
Swartz, M., Landerman, R., George, L. K., et al. Benzodiazepine antianxiety agents: Prevalence and correlates of use in a Southern community. American Journal of Public Health 81:592–596, 1991.
Busto, U., Sellers, E. M., Naranjo, C. A., et al. Patterns of benzodiazepine abuse and dependence. British Journal of Addictions 81:87–94, 1986.
Boixet, M., Batlle, E., & Bolibar, I. Benzodiazepines in primary health care: a survey of general practitioners prescribing patterns. Addiction 91:549–556, 1996.
Rickels, K., Case, W. G., Schweizer, E., et al. Long-term benzodiazepine users 3 years after participation in a discontinuation program. American Journal of Psychiatry 148:757–761, 1991.
Blennow, G., Romelsjö, A., Leifman, H., et al. Sedatives and hypnotics in Stockholm: Social factors and kinds of use. American Journal of Public Health 84:242–246, 1994.
Substance Abuse and Mental Health Services Administration, Office of Applied Studies. National household survey on drug abuse: Population estimates 1997. Rockville, MD: U.S. Department of Health and Human Services, 1998.
Johnston, L. D., O’Malley, P. M., & Bachman, J. G. National survey results on drug use from the Monitoring the Future Study, 1975–1997, Vol. I, Secondary School Students. Rockville, MD: National Institute on Drug Abuse, U.S. Department of Health and Human Services, 1998.
Royo-Bordonada, M. A., Cid-Ruzafa, J., Martin-Morena, J. M., & Guallar, E. Drug and alcohol use in Spain: Consumption habits, attitudes and opinions. Public Health 111:277–284, 1997.
Mora, M. E., Villatoro, J., & Rojas, E. Drug use among students in Mexico’s northern border states. In the Department of Health and Human Services, Epidemiologic trends in drug abuse. Washington, DC: U.S. Government Printing Office, 1996, pp. 367–375.
Ross, J., Darke, S., & Hall, W. Transitions between routes of benzodiazepine administration among heroin users in Sydney. Addiction 92:697–705, 1995.
Taylor, S., McCracken, C. F., Wilson, K. C., & Copeland, J. R. Extent and appropriateness of benzodiazepine use. Results from an elderly urban community. British Journal of Psychiatry 173:433–438, 1998.
Chang, G., & Kosten, T. R. Detoxification. In J. H. Lowinson, P. Ruiz, R. B. Millman, & J. G. Langrod (Eds.), Substance abuse: A comprehensive textbook (3rd ed.). Baltimore, MA: Williams & Wilkins, 1996, pp. 377–383.
Weinbroum, A. A., Flaishon, R., Sorkine, P., et al. A risk-benefit assessment of flumazenil in the management of benzodiazepine overdose. Drug Safety 17:181–196, 1997.
Woods, S. W., Rosen, M. I., Price, L. H., et al. Rapid benzodiazepine detoxification using flumazenil. Paper presented at the ACNP Annual Meeting, San Juan, December 14, 1992.
Nutt, D., & Costello, M. Flumazenil and benzodiazepine withdrawal. Lancet 2:463, 1987.
Boldy, D. A. R., Heath, A., Ruddock, S., et al. Activated charcoal for carbamazepine poisoning. Lancet 1:1027, 1987.
Editorial. Repeated oral activated charcoal in acute poisoning. Lancet 1:1013-1015, 1987.
Greenblatt, D. J., Miller, L. G., & Shader, R. I. Benzodiazepine discontinuation syndromes. Journal of Psychiatric Research 24:73–79, 1990.
Satel, S. L., Kosten, T. R., Schuckit, M. A., & Fischman, M. W. Should protracted withdrawal from drugs be included in DSM-IV? American Journal of Psychiatry 150:695–704, 1993.
Salzman, C. The APA task force report on benzodiazepine dependence, toxicity, and abuse. American Journal of Psychiatry 148:151–152, 1991.
Cowley, D. S., Roy-Byrne, P. P., Radant, A., et al. Benzodiazepine sensitivity in panic disorder: effects of chronic alprazolam treatment. Neuropsychopharmacology 12:147–157, 1995.
Cole, J. O., Haskell, D. S., & Orzack, M. H. Problems with the benzodiazepines: An assessment of the available evidence. McLean Hospital Journal 6:46–74, 1981.
Vinogradov, S., Reiss, A. L., & Csernansky, J. G. Clonidine therapy in withdrawal from high dose alprazolam treatment. American Journal of Psychiatry 143:1188, 1986.
Rickels, K., Schwizer, E., Case, G., & Greenblatt, D. J. Long-term therapeutic use of benzodiazepines. Archives of General Psychiatry 47:899–907, 1990.
DuPont, R. L. A practical approach to benzodiazepine discontinuation. Journal of Psychiatric Research 24:81–90, 1990.
Preskorn, S. H., & Denner, L. J. Benzodiazepines and withdrawal psychosis. Journal of the American Medical Association 237:36–38, 1977.
Sapira, J. D., & Cherubin, C. E. Drug abuse: A guide for the clinician. Amsterdam: Excerpta Medica/New York: American Elsevier, 1975.
Smith, D. E., & Wesson, D. R. Phenobarbital technique for treatment of barbiturate dependence. Archives of General Psychiatry 24:56–60, 1971.
The medical letter. Diagnosis and Management of Reactions to Drug Abuse, New Rochelle, NY: Vol. 19, Feb. 1977.
Schweizer, E., Rickels, K., Case, W. G., & Greenblatt, D. J. Carbamazepine treatment in patients discontinuing long-term benzodiazepine therapy. Archives of General Psychiatry 48:448–452, 1991.
DeMaria, Jr., P. A., Gottheil, E., Serota, R., & Sterling, R. C. Phenobarbital vs. clonazepam in the outpatient sedative detoxification of methadone-maintained persons. American Journal on Addictions 5:167–173, 1996.
Greenblatt, D. J., Harmatz, J. S., Shapiro, L., et al. Sensitivity to triazolam in the elderly. New England Journal of Medicine 324:1691–1698, 1991.
Cummings, S. R., Nevitt, M. C., Browner, W. S., et al. Risk factors for hip fracture in white women. New England Journal of Medicine 332:767–773, 1995.
Hemmelgarn, B., Suissa, S., Huang, A., et al. Benzodiazepine use and the risk of motor vehicle crash in the elderly. Journal of the American Medical Association 278:27–31, 1997.
Gorissen, M. E., & Eling, P. A. Dual task performance after diazepam intake: can resource depletion explain the benzodiazepine-induce amnesia? Psychopharmacology 138:354–361, 1998.
Anthenelli, R. M., Monteiro, M. G., Blunt, B., & Schuckit, M. A. Amnestic effects of intravenous diazepam in healthy young men. American Journal of Drug and Alcohol Abuse 17:129–136, 1991.
Tönne, U., Hiltunen, A. J., Vikander, B., et al. Neuropsychological changes during steady-state drug use, withdrawal and abstinence in primary benzodiazepine-dependent patients. Acta Psychiatrica Scandinavica 91:299–304, 1995.
Fraser, A. A., & Ingram, I. M. Lorazepam dependence and chronic psychosis. British Journal of Psychiatry 147:211, 1985.
Martínez-Cano, H., de Iceta Ibáñez de Gauna, M., Vela-Bueno, A., & Wittchen, H. U. DSM-III-R co-morbidity in benzodiazepine dependence. Addiction 94:97–107, 1999.
Brown, S. A., Irwin, M., & Schuckit, M. A. Changes in anxiety among abstinent male alcoholics. Journal of Studies on Alcohol 52:55–61, 1991.
Raimo, E. B., & Schuckit, M. A. Alcohol dependence and mood disorders. Addictive Behaviors 23:933–946, 1998.
Schuckit, M. A., Tipp, J. E., Bucholz, K. K., et al. The life time rates of three major mood disorders and four major anxiety disorders in alcoholics and controls. Addiction 92:1289–1304, 1997.
Schuckit, M. A., Tipp, J. E., Bergman, M., et al. Comparison of induced and independent major depressive disorders in 2,945 alcoholics. American Journal of Psychiatry 154:948–957, 1997.
Kripke, D. F., Klauber, M. R., Wingard, D. L., et al. Mortality hazard associated with prescription hypnotics. Biological Psychiatry 43:687–693, 1998.
Grant, I., Adams, K. M., & Reed, R. Subacute organic mental disorders. In I. Grant (Ed.), Neuropsychiatric correlates of alcoholism. Washington, DC: American Psychiatric Press, 1986, pp. 37–60.
Anthenelli, R. M., Klein, J. L., Smith, T L., & Schuckit, M. A. Comparison of the subjective and amnestic effects of diazepam and amobarbital in healthy young men. The American Journal of Addictions 2:131–140, 1993.
Barbone, F., McMahon, A. D., Davey, P. G., et al. Association of road-traffic accidents with benzodiazepine use. Lancet 352:1331–1336, 1998.
Schuckit, M. A. A clinical review of interactions among medications. Developmental Disabilities: Clinical Insights 11, San Diego Regional Center for the Developmentally Disabled, 1998.
Bergman, U., Rosa, F. W., Baum, C., Wilhom, B. E., & Faich, G. A. Effects of exposure to benzodiazepine during fetal life. Lancet 340:694–696, 1992.
Laegreid, L. Abnormalities in children exposed to benzodiazepines in utero. Lancet 1:108–109, 1987.
Kellogg, C. K., Simmons, R. D., Miller, R. K., & Ison, J. R. Prenatal diazepam exposure in rats: Long-lasting functional changes in the offspring. Neurobehavioral Toxicology and Teratology 7:483–488, 1985.
Author information
Authors and Affiliations
Rights and permissions
Copyright information
© 2000 Springer Science+Business Media New York
About this chapter
Cite this chapter
Schuckit, M.A. (2000). Central Nervous System Depressants. In: Drug and Alcohol Abuse. Critical Issues in Psychiatry. Springer, Boston, MA. https://doi.org/10.1007/978-1-4757-3232-0_2
Download citation
DOI: https://doi.org/10.1007/978-1-4757-3232-0_2
Publisher Name: Springer, Boston, MA
Print ISBN: 978-1-4757-3234-4
Online ISBN: 978-1-4757-3232-0
eBook Packages: Springer Book Archive